戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  42-52 years, and all were initially pre- or perimenopausal.
2 hese women were postmenopausal, and six were perimenopausal.
3 dlife adults, including 34 premenopausal, 39 perimenopausal, 27 postmenopausal women, and 37 men.
4 147,501 symptom logs (19% premenopausal, 39% perimenopausal, 42% menopausal).
5 des 4789 individuals (23% premenopausal, 29% perimenopausal, 48% menopausal) and 147,501 symptom logs
6 (mean [SD], 28.26 [5.05] years), 27 women of perimenopausal age (mean [SD] age, 45.21 [3.41] years; i
7                                   Within the perimenopausal age group, meeting Stages of Reproductive
8 rt of a change in a central biomarker during perimenopausal age that is also present during major dep
9                      On average, MAO-A VT in perimenopausal age was elevated by 34% compared with rep
10 antly lower in premenopausal (age 14-44) and perimenopausal (age 45-54) women than in men of the same
11                                   Similarly, perimenopausal (aged 40-50 y) and menopausal (aged 51-65
12 bar spine and femoral neck were performed in perimenopausal and early postmenopausal women aged 54.9
13                         If women are pre- or perimenopausal and have received 5 years of adjuvant tam
14 dence of ovarian cancer occurring during the perimenopausal and immediate postmenopausal periods.
15 oincided to draw increasing attention to the perimenopausal and menopausal years.
16                            Participants were perimenopausal and postmenopausal women aged 30 to 89 ye
17                                   Cases were perimenopausal and postmenopausal women aged 30 to 89 ye
18 ciated with invasive colon cancer risk among perimenopausal and postmenopausal women in the Californi
19           While PBC is predominantly seen in perimenopausal and postmenopausal women, men who are dia
20  myometrium from 186,120 cells across twenty perimenopausal and postmenopausal women.
21 ciated with risk of development of asthma in perimenopausal and postmenopausal women.
22 e implications for the choice of hormones in perimenopausal and postmenopausal women.
23  course of estrogen therapy on depression in perimenopausal and postmenopausal women.
24 idlife Health Project and included 17 early (perimenopausal) and continuous users of HT and 17 never
25            Thirteen were premenopausal, four perimenopausal, and 14 postmenopausal by history and hor
26  fat mass, and lean body mass in adolescent, perimenopausal, and elderly women, possibly as the resul
27 hnic cohort of women who were pre- and early perimenopausal at baseline, with multivariable, repeated
28                      Both the developing and perimenopausal brain are characterized by a sensitive pe
29 ne these measures in 45 premenopausal and 10 perimenopausal cycles alongside dates of supra-surge thr
30 y and premenstrual dysphoria was observed in perimenopausal depressed women.
31    The estimated 20-30% of women who develop perimenopausal depression (PMD) are at an increased risk
32 ectly test the estrogen withdrawal theory of perimenopausal depression (PMD).
33 ment of novel pharmacological treatments for perimenopausal depression and related disorders, such as
34 synthesized to describe a heuristic model of perimenopausal depression development.
35  steroids in both premenstrual dysphoria and perimenopausal depression has led to the suggestion that
36               Mood variability in women with perimenopausal depression may reflect episodic alteratio
37 ionship between ovarian function and mood in perimenopausal depression remains unclear.
38 cial environment of midlife to contribute to perimenopausal depression risk.
39 ion with onset in the menopause transition ("perimenopausal depression") involving alterations in str
40                   The relevant literature in perimenopausal depression, including prevalence, predict
41 ports of estradiol's therapeutic efficacy in perimenopausal depression, the relationship between ovar
42 ruptions in women, such as in postpartum and perimenopausal depression.
43  dysphoria was an invariant accompaniment of perimenopausal depression.
44 ry-ovarian axis function in women exhibiting perimenopausal depression.
45 strogen, in women who begin treatment in the perimenopausal/early postmenopausal period, whereas rand
46 mory performance for both postmenopausal and perimenopausal groups, and predicted presence of self-re
47     This study aimed to model the effects of perimenopausal hormonal fluctuations on AD pathophysiolo
48                  This study demonstrates how perimenopausal hormonal imbalances exacerbate AD risk vi
49 ion for atrial fibrillation, use of aspirin, perimenopausal hormone therapy, and psychosocial issues
50  (fMRI), we examined the long-term impact of perimenopausal HT use on brain function during performan
51                       Results indicated that perimenopausal HT users performed better than nonusers o
52                   During verbal recognition, perimenopausal HT users showed increased activation in t
53                       Premenopausal, but not perimenopausal, Japanese women whose intakes were greate
54  outcomes and intermediate CVD end points in perimenopausal, menopausal, or postmenopausal women.
55 ast 1 ovary, and were premenopausal or early perimenopausal (most recent menses <=3 months).
56 on and content patterns in healthy young and perimenopausal mouse ovaries.
57   Twenty-two depressed women who were either perimenopausal (N=10) or postmenopausal (N=12) received
58 2 to 52 years of age, premenopausal or early perimenopausal, not using hormone therapy, and free of C
59 of feeling "blue." The effect of being early perimenopausal on overall dysphoric mood was greatest am
60                                        Being perimenopausal or postmenopausal compared with being pre
61 rnia Teachers Study (1995-2006) among 56,864 perimenopausal or postmenopausal participants under 80 y
62 e forms of hormone therapy (HT) early in the perimenopausal or postmenopausal stage might confer bene
63 nd estrogen plus progestin therapy (EPT), in perimenopausal or postmenopausal women in all countries
64 , placebo-controlled clinical trial included perimenopausal or postmenopausal women reporting 7 or mo
65 en HRT is likely to offer health benefits to perimenopausal or postmenopausal women, including breast
66  sex-hormone levels during, for example, the perimenopausal or postpartum period appears to heighten
67 e 1, nonrandomized clinical trial analyzed 7 perimenopausal participants diagnosed with iSGS and foll
68                                     Of the 8 perimenopausal participants, 7 (median age, 50 years [IQ
69 , and fluorouracil (CMF; n = 300) in pre- or perimenopausal patients with ER-positive, node-positive
70 ction between RLS and sex (P = .044), with a perimenopausal peak retained only in women.
71 hort sleep duration during pregnancy and the perimenopausal period has been associated with adverse c
72                                          The perimenopausal period may be a critical juncture at whic
73 ne therapy when it is initiated early in the perimenopausal period or before the development of signi
74 mes and that starting hormone therapy in the perimenopausal period reduces these outcomes.
75 o an overall dysphoric mood during the early perimenopausal period.
76 enstrual cycle and during the postpartum and perimenopausal periods are associated with increased ris
77 ved during the premenstrual, postpartum, and perimenopausal phases, and when initiating hormonal cont
78 nd that HIV impacted burden most in the pre-/perimenopausal phases.
79 or premenopausal women vs. 0.008 mm/year for perimenopausal/postmenopausal women for AVG IMT; p = 0.0
80                  Additionally, among the 160 perimenopausal/postmenopausal women, the intervention sl
81                       Women who became early perimenopausal showed a 0.20-kg decline in pinch strengt
82 to ascertain which dietary factors influence perimenopausal skeletal loss.
83                   Continuous HT use from the perimenopausal stage versus no use was validated with pr
84 male C57BL/6 J and 3xTg mice, we simulated a perimenopausal state with hormonal changes characterised
85                           Self-assessment of perimenopausal status had the smallest negative LR (rang
86                                              Perimenopausal subjects were randomly assigned, double b
87 y after gynaecological surgery or to relieve perimenopausal symptoms.
88 ts had nearly 3 times the risk of an earlier perimenopausal transition (hazard ratio, 2.7; 95% confid
89             Depression often accompanies the perimenopausal transition and it often precedes overt sy
90  scores >8) had twice the risk of an earlier perimenopausal transition.
91 round the Nation, a prospective study of the perimenopausal transition.
92                   These results suggest that perimenopausal use of HT might confer long-term benefits
93 nondense breasts at mammography, and pre- or perimenopausal vs postmenopausal status for the two youn
94                   The first study focuses on perimenopausal weight gain, developed in response to a h
95 lts add to the literature by focusing on the perimenopausal weight trajectory and support efforts urg
96 2 clinical scenarios initiating therapy in a perimenopausal woman with hot flashes and discontinuing
97 istent mood symptoms were higher among early perimenopausal women (14.9%-18.4%) than among premenopau
98 ts (83.6% vs. 68.1%; P = 0.051), and pre- or perimenopausal women (87.1% vs. 81.7%; P = 0.057); and b
99                                              Perimenopausal women (aged 40-55 years, with irregular m
100 0.04 to 0.18; P=0.003), and premenopausal or perimenopausal women (difference, 0.15; 95 percent confi
101 s of testosterone concentrations in pre- and perimenopausal women (i.e., age, menopausal status, body
102                                              Perimenopausal women (n = 69) were randomly assigned (do
103 ing hormone (FSH) plasma levels of depressed perimenopausal women (N=110) attending a menopause clini
104  on plasma total antioxidant status (TAS) in perimenopausal women after control for other contributin
105 rse community cohort of 3,302 pre- and early perimenopausal women aged 42-52 years who were participa
106 neral density (BMD) in 1056 premenopausal or perimenopausal women aged 45-54 y and forearm bone mass
107 groups of women for whom HT is an indication-perimenopausal women and those soon after menopause who
108                         Studies that include perimenopausal women are needed to determine the efficac
109 enstrual cycle were examined in 70 depressed perimenopausal women attending a menopause clinic and 35
110  significantly increase blood lead levels in perimenopausal women because of postmenopausal bone mine
111               In a prospective cohort of 696 perimenopausal women enrolled in 2008-2012, we sought to
112                                              Perimenopausal women exhibited both menstrual cycle-asso
113                                              Perimenopausal women exhibited few differences in fiber
114 owed 3,302 initially premenopausal and early perimenopausal women from 7 US sites and 5 racial/ethnic
115  soy protein and low iron stores may protect perimenopausal women from oxidative stress.
116 e in a population based cohort study of 1240 perimenopausal women from the UK.
117  for major covariates and confounders, early perimenopausal women had higher odds of irritability, ne
118             Although hormone therapy (HT) in perimenopausal women is associated with increased risk f
119 e mineral density (BMD) and periodontitis in perimenopausal women is controversial.
120 sal women reported vasomotor symptoms, while perimenopausal women report both.
121                         Monitoring lipids in perimenopausal women should enhance primary prevention o
122 clinical symptoms and certain recent data in perimenopausal women suggest central nervous system invo
123      It is commonly an incidental finding in perimenopausal women undergoing screening mammography.
124  (OR = 1.6, 95% CI: 0.9, 3.0) and among pre-/perimenopausal women who had a high waist-hip ratio (OR
125                                         Some perimenopausal women with depression may benefit from sh
126 ne patterns of 572 of the 848 pre- and early-perimenopausal women with evidence of a luteal transitio
127                                      Pre- or perimenopausal women younger than 50 years who had dense
128  significantly better than film for pre- and perimenopausal women younger than 50 years with dense br
129 ustered microcysts are common, especially in perimenopausal women, and are seen in up to 6% of US exa
130 ng hormone-releasing hormone agonist in pre-/perimenopausal women, and men) until disease progression
131          In this sample of generally healthy perimenopausal women, low BMD was associated with clinic
132                                   Post-/pre-/perimenopausal women, or men, age 18 years or older with
133                Cognition seems to improve in perimenopausal women, possibly because menopausal sympto
134                                           In perimenopausal women, skeletal lead stores are an import
135 nt to the care of obese women, in particular perimenopausal women, undergoing bariatric surgery.
136  ER+PR+ breast cancer, especially among pre-/perimenopausal women.
137  and mild depressive symptoms experienced by perimenopausal women.
138 l connectivity relative to premenopausal and perimenopausal women.
139 ve disorders in endocrinologically confirmed perimenopausal women.
140  is an effective treatment of depression for perimenopausal women.
141 rption was estimated in 142 healthy pre- and perimenopausal women.
142 with isoflavones on bone or bone turnover in perimenopausal women.
143 ttenuated bone loss from the lumbar spine in perimenopausal women.
144 total BF and percentage BF than did pre- and perimenopausal women.
145  MHT regimens are not regulator approved for perimenopausal women.
146 common intracranial neoplasms, especially in perimenopausal women.
147 nding a menopause clinic and 35 nondepressed perimenopausal women.
148 likely play a role in the CV risk profile of perimenopausal women.
149 d Japanese) sample of 3297 premenopausal and perimenopausal women.
150 phically dense breasts, and premenopausal or perimenopausal women.
151 pituitary insensitivity to estrogen in aging perimenopausal women.
152 acy of a clinical examination in identifying perimenopausal women.These women should be counseled abo
153  although this difference declined after the perimenopausal years.
154 enopause was categorised as premenopausal or perimenopausal, younger than 40 years (premature menopau

 
Page Top